SG11201502849XA - Modified release formulations for oprozomib - Google Patents
Modified release formulations for oprozomibInfo
- Publication number
- SG11201502849XA SG11201502849XA SG11201502849XA SG11201502849XA SG11201502849XA SG 11201502849X A SG11201502849X A SG 11201502849XA SG 11201502849X A SG11201502849X A SG 11201502849XA SG 11201502849X A SG11201502849X A SG 11201502849XA SG 11201502849X A SG11201502849X A SG 11201502849XA
- Authority
- SG
- Singapore
- Prior art keywords
- oprozomib
- release formulations
- modified release
- modified
- formulations
- Prior art date
Links
- 108010064641 ONX 0912 Proteins 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title 1
- 229950005750 oprozomib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/066679 WO2014066681A1 (en) | 2012-10-24 | 2013-10-24 | Modified release formulations for oprozomib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201502849XA true SG11201502849XA (en) | 2015-05-28 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201502849XA SG11201502849XA (en) | 2012-10-24 | 2013-10-24 | Modified release formulations for oprozomib |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (cs) |
| EP (1) | EP2912025A4 (cs) |
| JP (1) | JP6505604B2 (cs) |
| KR (1) | KR20150070406A (cs) |
| CN (1) | CN104968650A (cs) |
| AP (1) | AP3681A (cs) |
| AR (1) | AR093126A1 (cs) |
| AU (1) | AU2013334258A1 (cs) |
| BR (1) | BR112015008572A2 (cs) |
| CA (1) | CA2888039A1 (cs) |
| CL (1) | CL2015001085A1 (cs) |
| CR (1) | CR20150266A (cs) |
| EA (1) | EA201590797A1 (cs) |
| HK (2) | HK1208222A1 (cs) |
| IL (1) | IL238244A0 (cs) |
| IN (1) | IN2015DN03921A (cs) |
| MX (1) | MX2015005069A (cs) |
| PE (1) | PE20151051A1 (cs) |
| PH (1) | PH12015500823A1 (cs) |
| SG (1) | SG11201502849XA (cs) |
| TN (1) | TN2015000135A1 (cs) |
| TW (1) | TW201422255A (cs) |
| UY (1) | UY35091A (cs) |
| WO (1) | WO2014066681A1 (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| HK1252549A1 (zh) | 2015-06-19 | 2019-05-31 | Biotie Therapies, Inc. | 控释tozadenant制剂 |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| WO2018005781A1 (en) * | 2016-06-29 | 2018-01-04 | Kezar Life Sciences | Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof |
| WO2018057453A1 (en) | 2016-09-21 | 2018-03-29 | Amgen Inc. | Immediate release formulations for oprozomib |
| WO2018112078A1 (en) | 2016-12-14 | 2018-06-21 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| US11401334B2 (en) | 2017-09-14 | 2022-08-02 | Glaxosmithkline Intellectual Property Development Limited | Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitor |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| JP2025516629A (ja) | 2022-05-11 | 2025-05-30 | セルジーン コーポレーション | Ｔ細胞療法に関連する方法および使用、ならびにその生成 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| AU4499697A (en) | 1996-09-13 | 1998-04-02 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| BR0207157A (pt) * | 2001-02-12 | 2004-02-17 | Wyeth Corp | Sal de succinato de o-desmetil-venlafaxina |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| LT2623113T (lt) * | 2005-11-09 | 2017-07-10 | Onyx Therapeutics, Inc. | Junginiai, skirti fermentų slopinimui |
| US20100172988A1 (en) * | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| ES2684340T3 (es) * | 2007-10-04 | 2018-10-02 | Onyx Therapeutics, Inc. | Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos |
| TWI504598B (zh) * | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
-
2013
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en not_active Ceased
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015005069A (es) | 2015-07-17 |
| IN2015DN03921A (cs) | 2015-10-02 |
| JP6505604B2 (ja) | 2019-04-24 |
| PH12015500823A1 (en) | 2015-06-22 |
| KR20150070406A (ko) | 2015-06-24 |
| HK1215709A1 (zh) | 2016-09-09 |
| BR112015008572A2 (pt) | 2017-07-04 |
| AR093126A1 (es) | 2015-05-20 |
| CR20150266A (es) | 2015-08-14 |
| TW201422255A (zh) | 2014-06-16 |
| IL238244A0 (en) | 2015-06-30 |
| EP2912025A4 (en) | 2016-06-08 |
| JP2015535255A (ja) | 2015-12-10 |
| AP3681A (en) | 2016-04-19 |
| CL2015001085A1 (es) | 2015-08-28 |
| UY35091A (es) | 2014-05-30 |
| EA201590797A1 (ru) | 2016-02-29 |
| AP2015008387A0 (en) | 2015-04-30 |
| HK1208222A1 (en) | 2016-02-26 |
| CN104968650A (zh) | 2015-10-07 |
| US20140113855A1 (en) | 2014-04-24 |
| WO2014066681A1 (en) | 2014-05-01 |
| CA2888039A1 (en) | 2014-05-01 |
| AU2013334258A1 (en) | 2015-04-30 |
| TN2015000135A1 (en) | 2016-10-03 |
| US9295708B2 (en) | 2016-03-29 |
| US20160213610A1 (en) | 2016-07-28 |
| EP2912025A1 (en) | 2015-09-02 |
| PE20151051A1 (es) | 2015-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201500212B (en) | Progesterone formulations | |
| IL234256B (en) | Tamper resistant immediate release formulations | |
| SI3117837T1 (sl) | Formulacije protiteles | |
| ZA201509340B (en) | Proliposomal testosterone formulations | |
| IL236304A0 (en) | Formulations for diclofenac | |
| ZA201202474B (en) | Controlled release compositions | |
| ZA201503603B (en) | Composition for immediate and extended release | |
| AP3681A (en) | Modified release formulations for oprozomib | |
| GB201812591D0 (en) | Brake | |
| HUE071706T2 (hu) | Triazin készítmények | |
| GB201210530D0 (en) | Extended release formulations | |
| EP2840704A4 (en) | RETARDER | |
| GB201221125D0 (en) | Pharmaceutial formulations | |
| GB201206178D0 (en) | Formulations | |
| IL220200A (en) | Release device | |
| HUP1100207A2 (en) | Modified release composition | |
| GB201111578D0 (en) | Pharmeutical formulations | |
| GB201111013D0 (en) | Formulations | |
| GB201107627D0 (en) | Formulations | |
| GB201107626D0 (en) | Formulations | |
| GB201105410D0 (en) | Formulations | |
| GB201105360D0 (en) | Formulations | |
| GB201104049D0 (en) | Formulations | |
| GB201104048D0 (en) | Formulations | |
| GB201102795D0 (en) | Formulations |